Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $33.39M fell 7.4% year over year, behind the -0.7% change in trailing-twelve-month operating expenses. Sequentially, it fell 14.8% from the prior quarter. Over 3 fiscal years it compounded at -22.5% a year.

Context

  • Operating expenses amounted to 353.8% of revenue in FY2025, up 74.0 pp from a year earlier.
  • Operating expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -7.4% toward the trailing-twelve-month pace of -0.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$33.39M-14.8% QoQ
Last fiscal yearDec 2025
$139.95M-13.5% YoY
LTMMar 2026
$144.88M-0.7% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.4%——
1 year-13.5%——
3-year CAGR-22.5%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
139.95M USD
Year-over-year change
-13.5%
4-year CAGR
-16.9%

Operating Expenses vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.7% is the 3rd highest of 11, against a peer median of -11.7%.
  • Operating expenses amounts to 419.2% of revenue for SGMO, versus a peer median of 1187.9%.
SGMO Competitors
Operating Expenses for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CCCCC4 Therapeutics, Inc.LTM Mar 2026$146.9M USD-2.4%-6.2%421.4%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$144.88M USD-0.7%-22.5%419.2%
IVVDInvivyd, Inc.LTM Mar 2026$133.18M USD-26.8%-24.9%238.4%
CDXSCodexis, Inc.LTM Mar 2026$91.44M USD-11.0%-9.8%117.1%
OABIOmniAb, Inc.LTM Mar 2026$68.18M USD-30.1%-7.4%235.8%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$67.15M USD+28.8%-0.4%3764.1%
MOLNMolecular Partners AGLTM Mar 2026CHF 63.08M CHF+100.0%-11.3%—
IPHAInnate Pharma S.A.FY2025€56.21M EUR-12.4%-3.9%2016.9%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$41.55M USD-31.4%+19.6%2131.9%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$39.36M USD-9.9%+66.9%1330.7%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$37.64M USD-28.3%-14.9%1187.9%
Peer median (excluding SGMO) —-11.7%-6.8%1187.9%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110.7M111.3M176.23M57.8M39.55M
Cost of Revenue012.11M007.6M
Gross Profit110.7M99.19M176.23M57.8M31.95M
Gross Margin100.0%89.1%100.0%100.0%80.8%
Research & Development230.82M249.9M234.06M111.52M112.67M
Selling, General & Admin63.22M62.68M61.17M44.73M34.89M
Operating Expenses294.04M300.47M450.24M161.77M139.95M
Depreciation & Amortization17.64M12.11M22.19M9.36M7.6M
EBITDA(160.35M)(179.74M)(96.8M)(89.09M)(115.9M)
EBITDA Margin-144.9%-161.5%-54.9%-154.1%-293.0%
Operating Income(183.34M)(201.28M)(274.01M)(103.97M)(108M)
Operating Margin-165.6%-180.8%-155.5%-179.9%-273.1%
Interest Income5.35M9.43M11.1M5.86M1.3M
Interest Expense00000
Other Income / Expenses5.35M9.43M11.1M5.86M(15.5M)
Income Before Tax(177.99M)(191.85M)(262.9M)(98.11M)(123.5M)
Pre-Tax Margin-160.8%-172.4%-149.2%-169.7%-312.2%
Income Tax Expense306K429K(5.07M)(167K)(568K)
Net Income(178.29M)(192.28M)(257.83M)(97.94M)(122.93M)
Net Margin-161.1%-172.8%-146.3%-169.4%-310.8%
EPS (Basic)(1.23)(1.25)(1.48)(0.49)(0.44)
EPS (Diluted)(1.23)(1.25)(1.48)(0.49)(0.44)
Weighted Avg Shares144.57M154.35M174.44M201.7M280.19M
Weighted Avg Shares (Diluted)144.57M154.35M174.44M201.7M280.19M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.